• Molecular NameNelarabine
  • SynonymGW-506U78; nelarabine; Nelzarabine
  • Weight297.271
  • Drugbank_IDDB01280
  • ACS_NO121032-29-9
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-0.95
  • pka2.5; 12.1
  • LogD (pH=7, predicted)-0.95
  • Solubility (experiment)Soluble
  • LogS (predicted, ACD/Labs)(ph=7)-2.57
  • LogSw (predicted, AB/LogsW2.0)8.22
  • Sw (mg/ml) (predicted, ACD/Labs)0.8
  • No.of HBond Donors5
  • No.of HBond Acceptors10
  • No.of Rotatable Bonds3
  • TPSA148.77
  • StatusFDA approved
  • AdministrationIntravenous
  • PharmacologyA chemotherapy drug used in T-cell acute lymphoblastic leukemia.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability11.0
  • Protein binding25.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmBy adenosine deaminase, to 9-β-D-arabinofuranosylguanine
  • Half life0.5 h (nelarabine); 3 hours (ara-G)
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe most common adverse events in pediatric patients, regardless of causality, were hematologic disorders (anemia, leukopenia, neutropenia, and thrombocytopenia).
  • LD50 (rat)N/A
  • LD50 (mouse)N/A